Core Points - The document outlines the rules for the shareholders' meeting of Guangxi Liuyao Group Co., Ltd, ensuring compliance with relevant laws and regulations [2][22] - It specifies the procedures for convening, proposing, notifying, and conducting shareholders' meetings, emphasizing the rights of shareholders to participate and vote [4][10] Group 1: General Provisions - The rules are established to regulate the behavior of the company and ensure shareholders can exercise their rights according to the law [2] - The company must strictly follow legal and regulatory requirements when convening shareholders' meetings [3] Group 2: Convening Shareholders' Meetings - The board of directors is responsible for convening the annual and temporary shareholders' meetings within specified timeframes [4][5] - Independent directors and the audit committee have the right to propose temporary meetings, and the board must respond within ten days [8][9] Group 3: Proposals and Notifications - Shareholders holding more than 1% of shares can propose agenda items for the meeting, with specific timelines for submission [14][15] - Notifications for meetings must be sent out in advance, detailing all proposals and necessary information for shareholders to make informed decisions [16][17] Group 4: Conducting Shareholders' Meetings - Meetings must be held at the company's registered location or another specified venue, allowing for both in-person and remote participation [21][22] - The meeting must be presided over by the chairman or a designated representative, ensuring order and adherence to the agenda [30][31] Group 5: Voting Procedures - Resolutions can be classified as ordinary or special, with different voting thresholds required for approval [34][36] - Shareholders must vote on each proposal individually, and the results must be publicly announced [46][48] Group 6: Meeting Records - Detailed records of the meeting must be maintained, including attendance, proposals discussed, and voting outcomes [52] - The records should be preserved for a minimum of ten years to ensure transparency and accountability [52]

广西柳药集团股份有限公司 第一章 总则 第一条 为规范广西柳药集团股份有限公司（以下简称"柳药集团"或"公 司"）2025 年员工持股计划（以下简称"员工持股计划"或"本计划"）的实施， 根据《中华人民共和国公司法》（以下简称"《公司法》"）、《中华人民共和国证 券法》（以下简称"《证券法》"）、《关于上市公司实施员工持股计划试点的指导 意见》（以下简称"《指导意见》"）、《上海证券交易所上市公司自律监管指引第 （以下简称"《规范运作》"）等相关法律、行政法规、规章、 规范性文件和《公司章程》、《广西柳药集团股份有限公司 2025 年员工持股计划 （草案）》之规定，特制定《广西柳药集团股份有限公司 2025 年员工持股计划管 理办法》（以下简称"本办法"）。 第二章 员工持股计划的制定 第二条 员工持股计划的目的 公司依据《公司法》《证券法》《指导意见》《规范运作》等有关法律、行政 法规、规章、规范性文件和《公司章程》的规定，制定了本计划。公司员工自愿、 合法、合规地参与员工持股计划，持有公司股票的目的在于建立和完善员工、股 东的利益共享机制，改善公司治理水平，提高职工的凝聚力和公司竞争力，调动 员工的积极性 ...

广西柳药集团股份有限公司 董事会薪酬与考核委员会工作细则 （2025 年 8 月修订） 第一章 总则 第一条 为进一步建立健全广西柳药集团股份有限公司（以下简称"公司"） 董事、高级管理人员的薪酬与考核管理制度，完善公司治理结构，有效实施公司 人才发展战略，根据《中华人民共和国公司法》 经董事长提议并经董事会讨论通过，可对委员会委员在任期内进行调整。 《上市公司治理准则》 《上海证券 交易所上市公司自律监管指引第 1 号——规范运作》等法律、法规和规范性文件 及《广西柳药集团股份有限公司章程》（以下简称"《公司章程》"）等有关规定， 公司设立董事会薪酬与考核委员会（以下简称"薪酬与考核委员会"），并结合公 司实际情况，制订本细则。 第二条 薪酬与考核委员会是董事会下设的专门委员会，主要负责制定公司 董事、高级管理人员的考核标准并进行考核；制定、审查公司董事、高级管理人 员的薪酬决定机制、决策流程、支付与止付追索安排等薪酬政策与方案，并提出 建议。 第三条 本细则所称董事是指在公司领取薪酬的非独立董事；高级管理人员 是指董事会聘任的总裁、副总裁、董事会秘书、财务总监及由总裁提请董事会认 定的其他高级管理人员。 ...

Core Points - The article outlines the establishment and operational guidelines of the Strategic Committee of Guangxi Liuyuan Pharmaceutical Group Co., Ltd. to enhance the company's core competitiveness and improve decision-making processes [1][2] - The Strategic Committee is responsible for researching and proposing suggestions on the company's long-term development strategies and major investment decisions [1][2] Group 1: General Provisions - The Strategic Committee is established to meet the strategic development needs of the company and to enhance its core competitiveness [1] - The committee is a specialized body under the board of directors, focusing on long-term strategies and significant investment decisions [1][2] Group 2: Composition of the Committee - The Strategic Committee consists of three directors, including at least one independent director [2] - The committee members are nominated by the chairman, a majority of independent directors, or at least one-third of all directors, and elected by the board [2] Group 3: Responsibilities and Authority - The main responsibilities of the Strategic Committee include researching long-term development strategies, evaluating major investment decisions, and checking the implementation of these matters [3][4] - The committee is accountable to the board of directors and must report its work and proposals for board review [3] Group 4: Decision-Making Procedures - The Investment Review Group, led by the company's president, prepares the necessary materials for the Strategic Committee's decisions [4][5] - The committee must hold meetings to discuss proposals from the Investment Review Group and submit the results to the board [4][5] Group 5: Meeting Rules - The Strategic Committee must hold at least one regular meeting annually, with provisions for additional meetings as needed [5][6] - Meetings require the presence of at least two-thirds of the committee members to be valid, and decisions must be approved by a majority [6][7] Group 6: Confidentiality and Record-Keeping - All participants in the committee meetings are bound by confidentiality regarding the discussed matters [7][8] - Meeting records must be maintained for at least ten years, and the committee's proposals must be submitted in writing to the board [7][8]

广西柳药集团股份有限公司 董事会提名委员会工作细则 （2025 年 8 月修订） 第一章 总则 第一条 为完善广西柳药集团股份有限公司（以下简称"公司"）的法人治 理结构，规范董事会成员和高级管理人员的产生，优化董事会组成，根据《中华 人民共和国公司法》《上市公司治理准则》《上海证券交易所上市公司自律监管 指引第 1 号——规范运作》等法律、法规和规范性文件及《广西柳药集团股份有 限公司章程》（以下简称"《公司章程》"）等有关规定，公司设立董事会提名 委员会（以下简称"提名委员会"），并结合公司实际情况，制订本细则。 第二条 提名委员会是董事会下设的专门委员会，主要负责拟定董事、高级 管理人员的选择标准和程序，对董事、高级管理人员人选及其任职资格进行遴选、 审核并提出建议。 第二章 人员组成 第三条 提名委员会由三名董事组成，其中独立董事应当过半数。 第四条 提名委员会委员由董事长、1/2 以上独立董事或者全体董事的 1/3 以 上提名，并由董事会选举产生。 第五条 提名委员会设主任委员（召集人）一名，由独立董事担任，负责主 持委员会工作。提名委员会主任委员由董事长提名，并经全体董事过半数选举产 生。 第七条 ...

Core Viewpoint - The document outlines the establishment and operational guidelines of the Audit Committee of Guangxi Liuyuan Pharmaceutical Group Co., Ltd, emphasizing its role in enhancing corporate governance and ensuring effective oversight of financial reporting and internal controls [1][2]. Group 1: General Provisions - The Audit Committee is established to improve the company's governance structure and ensure effective supervision of management [1]. - The committee is responsible for reviewing financial information, supervising internal and external audits, and evaluating internal controls [2]. Group 2: Composition of the Committee - The committee consists of at least three directors, with a majority being independent directors, and is chaired by an independent director with accounting expertise [3][4]. - The term of committee members aligns with their term as directors, and they can be re-elected [3][4]. Group 3: Responsibilities and Authority - The main responsibilities include reviewing financial reports, supervising management actions, proposing meetings, and evaluating external audit work [5][6]. - The committee must approve significant financial disclosures and the hiring or dismissal of external auditors [6][7]. Group 4: Internal Audit Oversight - The committee guides and supervises the internal audit department, reviews audit plans, and evaluates the effectiveness of internal controls [8][9]. - It is required to conduct checks on high-risk activities and report any violations to the relevant authorities [9]. Group 5: Meeting Procedures - The committee must hold at least one meeting per quarter, with provisions for special meetings as needed [12][13]. - A quorum of two-thirds of members is required for meetings, and decisions are made by majority vote [13][14]. Group 6: Information Disclosure - The company must disclose the composition and activities of the Audit Committee in its annual reports, including any significant issues identified during its oversight [16][17]. - Any recommendations made by the committee that are not adopted by the board must be disclosed with explanations [17].

Core Viewpoint - Guangxi Liuyuan Group Co., Ltd. is undergoing significant changes in its corporate governance structure, including a capital reduction, the cancellation of the supervisory board, and amendments to its articles of association to enhance governance efficiency and compliance with regulations [1][3][4]. Capital Change Summary - The company has approved a capital reduction from RMB 398,863,861 to RMB 397,168,905 due to the repurchase and cancellation of 1,695,050 restricted shares [2][4]. - The conversion of convertible bonds has resulted in a total of 94 shares being converted from the "Liuyuan Convertible Bonds" since their issuance [1]. Cancellation of Supervisory Board - The decision to cancel the supervisory board is based on the need to align corporate governance with regulatory requirements and the company's operational realities, with the audit committee of the board taking over its responsibilities [3][4]. - The supervisory board will continue to fulfill its duties until the shareholders' meeting approves the cancellation [3]. Amendments to Articles of Association - The articles of association will be comprehensively revised to reflect the changes in capital structure and the cancellation of the supervisory board, including the removal of references to the supervisory board and the strengthening of responsibilities for controlling shareholders and independent directors [4][5]. - Specific amendments include the unification of terms related to the shareholders' meeting and the removal of the supervisory board section, along with adjustments to enhance governance effectiveness [4][5]. Other Governance System Revisions - The company plans to revise and establish several governance systems to improve operational standards, which will require shareholder approval for certain amendments [4][5]. - The proposed changes include updates to the management of shares held by directors and senior management, which will take effect upon board approval for most items [4].

证券代码：603368 证券简称：柳药集团 公告编号：2025-062 广西柳药集团股份有限公司（以下简称"公司"）于 2025 年 8 月 28 日在公 司会议室采用现场表决的方式召开职工代表大会。本次会议的召集、召开及表决 程序符合公司职工代表大会制度的有关规定，会议合法、有效。 二、职工代表大会审议情况 经全体与会职工代表民主讨论，审议并通过了如下议案： 转债代码：113563 转债简称：柳药转债 （一）审议通过《关于 <广西柳药集团股份有限公司 ensp="ensp" 年员工持股计划="年员工持股计 划"> （草案）>及其摘要的议案》 广西柳药集团股份有限公司 《广西柳药集团股份有限公司 2025 年第一期员 关于职工代表大会决议公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担个别及连带责任。 一、职工代表大会召开情况 证券法》 《关于上市公司实施员工持股计划试点的指导意见》 《上海证券交易所上 市公司自律监管指引第 1 号——规范运作》等法律、法规、规范性文件及《公司 章程》等有关规定，公司遵循依法合规、自愿参与、风险自担 ...

证券简称：柳药集团 证券代码：603368 广西柳药集团股份有限公司 二〇二五年八月 声明 本公司及全体董事保证本员工持股计划及其摘要不存在任何虚假记载、误导 性陈述或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 风险提示 一、广西柳药集团股份有限公司（以下简称"柳药集团""公司"或"本公 司"）2025 年员工持股计划（草案）（以下简称"本员工持股计划草案"）须 经公司股东会批准后方可实施，本员工持股计划草案能否获得公司股东会批准， 存在不确定性。 二、有关公司 2025 年员工持股计划（以下简称"本员工持股计划"）的 具体的资金来源、出资金额、预计规模和具体实施方案等属初步结果，能否 完成实施，存在不确定性。 三、若员工认购资金较低，本员工持股计划存在无法成立的风险；若员 工认购份额不足，本员工持股计划存在低于预计规模的风险。 四、股票价格受公司经营业绩、宏观经济周期、国际/国内政治经济形势及 投资者心理等多种复杂因素影响。因此，股票交易是有一定风险的投资活动，投 资者对此应有充分准备。 五、敬请广大投资者谨慎决策，注意投资风险。 特别提示 本部分内容中的词语简称与"释义"部分保持一致。 ...

董事 28 日 29 日 工作调整 （二）离任对公司影响 公司于 2025 年 8 月 28 日召开职工代表大会，经全体与会职工代表认真审议 并表决，一致同意选举唐春雪女士（简历详见附件）为公司第五届董事会职工代 表董事，与经公司股东会选举产生的现任非职工代表董事共同组成公司第五届董 事会，任期自本次职工代表大会选举通过之日起至第五届董事会届满之日止。 | | 证券代码：603368 证券简称：柳药集团 公告编号：2025-063 | | | | | | | --- | --- | --- | --- | --- | --- | --- | | | 转债代码：113563 转债简称：柳药转债 | | | | | | | | 广西柳药集团股份有限公司 | | | | | | | | 关于非独立董事辞职暨选举职工代表董事的公告 | | | | | | | | 本公司监事会及全体监事保证本公告内容不存在任何虚假记载、误导性陈述 | | | | | | | | 或者重大遗漏，并对其内容的真实性、准确性和完整性承担个别及连带责任。 | | | | | | | | 一、关于非独立董事辞职的情况 | | | | | | | ...